| N07XX09 |
Dimethyl fumarate |
Tecfidera |
Gastro‐resistant capsule, hard |
120 |
mg |
14 |
Biogen Idec Limited, Германия |
480 |
mg |
299.59 |
- |
76.28357 |
266.99 |
100% |
266.99 |
За експертиза по чл. 78 т.2 от ЗЗО |
G35 |
НСР-7451/10.11.2015.; НСР-9971/29.07.2016. |
16.11.2015.; 02.09.2016. |
|
|
Активен |
4094 |
Без промяна |
| P01BA01 |
Chloroquine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| P01BA01 |
Chloroquine |
RESOCHIN |
Film‐coated tablet |
250 |
mg |
100 |
Bayer Pharma AG, Германия |
500 |
mg |
- |
41.41 |
0.8282 |
41.41 |
25% |
10.35 |
|
M05.0,M05.1,M05.2,M05.3,M05.8,M07.1,M08.3,M08.4,M32.0,M32.1,M32.8 |
|
|
08.09.2012 |
|
Активен |
364 |
Без промяна |
| P02CA03 |
Albendazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| P02CA03 |
Albendazole |
ZENTEL |
Tablet |
400 |
mg |
1 |
ГлаксоСмитКлайн ЕООД, България |
400 |
mg |
3.05 |
- |
3.05 |
3.05 |
100% |
3.05 |
За експертиза по чл. 78 т.2 от ЗЗО |
B67.0,B67.1,B67.3,B67.5,B67.6 |
№ 190/ 22.08.2011; КЦРР-2590/14.03.2013 г; НСР-3391/29.04.2014; НСР-6677/09.07.2015 |
02.08.2015 |
08.09.2012 |
16.11.2013 |
Активен |
2784 |
Без промяна |
| R03AC02; R03CC02 |
Salbutamol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AC02 |
Salbutamol |
BUTO-ASMA |
Pressurised inhalation, suspension |
0,1 mg/dose - 200 doses |
mg |
1 |
Чайкафарма Висококачествените лекарства АД, България |
0.8 |
mg |
5.16 |
- |
0.01608 |
4.02 |
100% |
4.02 |
|
J44.8,J45.0,J45.1 |
|
16.02.2014 |
08.09.2012 |
|
Активен |
564 |
Без промяна |
| R03AC02 |
Salbutamol |
Ecosal Easi-Breathe |
Pressurised inhalation, suspension |
0,1 mg/dose - 200 doses |
mg |
1 |
Teva Czech Industries s.r.o., Чешка република |
0.8 |
mg |
6.5 |
- |
0.01608 |
4.02 |
100% |
4.02 |
|
J44.8,J45.0,J45.1 |
№ 121/ 09.12.2010; КЦРР-1199/13.08.2012 г.; НСР-70/07.06.2013; НСР-2631/03.02.2014; НСР-5962/01.04.2015. |
02.05.2015 |
08.09.2012 |
|
Активен |
3785 |
Без промяна |
| R03AC02 |
Salbutamol |
Ecosal Inhaler |
Pressurised inhalation, suspension |
0,1 mg/dose - 200 doses |
mg |
1 |
Teva Czech Industries s.r.o., Чешка република |
0.8 |
mg |
5.9 |
- |
0.01608 |
4.02 |
100% |
4.02 |
|
J44.8,J45.0,J45.1 |
№ 121/ 09.12.2010 |
16.02.2014 |
08.09.2012 |
|
Активен |
663 |
Без промяна |
| R03AC02 |
Salbutamol |
SALBUTAMOL INHALER |
Pressurised inhalation, suspension |
100 mcg/metered actuation - 200 doses |
mg |
1 |
Glaxo Group Ltd., Обединено Кралство |
0.8 |
mg |
4.02 |
- |
0.01608 |
4.02 |
100% |
4.02 |
|
J44.8,J45.0,J45.1 |
№ 101/ 20.09.2010; КЦРР-2665/20.03.2013 г.; НСР-2429/21.01.2014 |
16.02.2014 |
08.09.2012 |
|
Активен |
2452 |
Без промяна |
| R03CC02 |
Salbutamol |
Salbutamol Sandoz |
Pressurised inhalation, suspension |
100 mcg/dose - 200 doses |
mg |
1 |
Sandoz d.d., Словения |
0.8 |
mg |
4.09 |
- |
0.01608 |
4.02 |
100% |
4.02 |
|
J44.8,J45.0,J45.1 |
НСР-1636/11.11.2013 |
16.02.2014 |
|
|
Активен |
2246 |
Без промяна |
| R03AC12 |
Salmeterol xinafoate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AC12 |
Salmeterol |
Serevent inhaler |
Pressurised inhalation, suspension |
25 mcg/dose x 120 doses |
mg |
1 |
ГлаксоСмитКлайн ЕООД, България |
0.1 |
mg |
32.04 |
- |
1.068 |
32.04 |
100% |
32.04 |
|
J44.8,J45.0,J45.1 |
КЦРР-1203/13.08.2012 г.; HCР-273/28.06.2013; НСР-3201/07.04.2014; НСР-5209/04.12.2014 |
02.01.2015 |
08.09.2012 |
|
Активен |
3433 |
Без промяна |
| R03AC18 |
Indacaterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AC18 |
Indacaterol |
Onbrez Breezhaler |
Inhalation powder, hard capsule |
150 |
mcg |
30 |
Novartis Europharm Limited, Обединено Кралство |
1 |
mcg |
- |
59.57 |
0.01324 |
59.57 |
75% |
44.68 |
|
J44.8 |
; НСР-9221/ 05.05.2016 |
02.06.2016 |
08.09.2012 |
|
Активен |
3546 |
Без промяна |
| R03AC19 |
Olodaterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AC19 |
Olodaterol |
Striverdi Respimat |
Inhalation solution |
2,5 |
mcg |
1 respimat inhaler and 1 cartridge (60 doses) |
Boehringer Ingelheim International GmbH, Германия |
5 |
mcg |
- |
59.14 |
1.97133 |
59.14 |
75% |
44.36 |
|
J44.8 |
НСР-7563/24.11.2015 |
02.12.2015 |
|
|
Активен |
4113 |
Без промяна |
| R03AK06 |
Salmeterol xinafoate/ Fluticasone propionate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK06 |
Salmeterol, Fluticasone |
AirFluSal Forspiro |
Inhalation powder, pre‐dispensed |
50 mcg/250 mcg/dose - 60 doses |
UD |
1 |
Sandoz d.d., Словения |
2 |
UD |
68.74 |
- |
1.86467 |
55.94 |
100% |
55.94 |
|
J45.0,J45.1 |
; НСР-9202/05.05.2016 |
02.06.2016 |
|
|
Активен |
4060 |
Без промяна |
| R03AK06 |
Salmeterol, Fluticasone |
AirFluSal Forspiro |
Inhalation powder, pre‐dispensed |
50 mcg/500 mcg/ dose-60 doses |
UD |
1 |
Sandoz Pharmaceuticals GmbH, Германия |
2 |
UD |
86.77 |
- |
2.83867 |
85.16 |
100% |
85.16 |
|
J44.8,J45.0,J45.1 |
НСР-4246/30.07.2014.; НСР-7270/21.10.2015. |
16.11.2015 |
|
|
Активен |
3051 |
Без промяна |
| R03AK06 |
Salmeterol, Fluticasone |
SERETIDE DISCUS |
Inhalation powder |
50 mcg/100 mcg/dose - 60 doses |
UD |
1 |
ГлаксоСмитКлайн ЕООД, България |
2 |
UD |
41.72 |
- |
1.39067 |
41.72 |
100% |
41.72 |
|
J45.0,J45.1 |
; НСР-9233/05.05.2016 |
02.06.2016 |
08.09.2012 |
|
Активен |
3879 |
Без промяна |
| R03AK06 |
Salmeterol, Fluticasone |
SERETIDE DISCUS |
Inhalation powder |
50 mcg/250 mcg/dose - 60 doses |
UD |
1 |
ГлаксоСмитКлайн ЕООД, България |
2 |
UD |
55.94 |
- |
1.86467 |
55.94 |
100% |
55.94 |
|
J45.0,J45.1 |
; НСР-9233/05.05.2016 |
02.06.2016 |
08.09.2012 |
|
Активен |
3331 |
Без промяна |
| R03AK06 |
Salmeterol, Fluticasone |
SERETIDE DISCUS |
Inhalation powder |
50 mcg/500 mcg/dose - 60 doses |
UD |
1 |
ГлаксоСмитКлайн ЕООД, България |
2 |
UD |
85.16 |
- |
2.83867 |
85.16 |
100% |
85.16 |
|
J44.8,J45.0,J45.1 |
№26/04.08.2009; № 67/ 08.04.2010 / №37/21,08,2009; НСР-4601/15.09.2014 |
16.10.2014 |
08.09.2012 |
|
Активен |
3205 |
Без промяна |
| R03AK07 |
Budesonide/Formoterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK07 |
Budesonide, Formoterol |
DuoResp® Spiromax® |
Inhalation powder |
160 mcg/4,5 mcg/dose - 120 doses |
UD |
1 |
Teva Pharma B.V., Нидерландия |
4 |
UD |
79.26 |
- |
2.30067 |
69.02 |
100% |
69.02 |
не се прилага на лица под 18 години |
J44.8,J45.0,J45.1 |
НСР-4735/02.10.2014 |
02.06.2016 |
|
|
Активен |
4016 |
Без промяна |